Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E32.58 EPS (ttm)19.90 Insider Own1.10% Shs Outstand109.80M Perf Week2.76%
Market Cap66.33B Forward P/E19.91 EPS next Y32.56 Insider Trans-42.29% Shs Float87.31M Perf Month3.38%
Income2.28B PEG3.68 EPS next Q5.98 Inst Own80.90% Short Float2.28% Perf Quarter12.89%
Sales7.98B P/S8.31 EPS this Y-10.80% Inst Trans5.16% Short Ratio1.56 Perf Half Y82.14%
Book/sh110.50 P/B5.87 EPS next Y19.69% ROA15.80% Target Price643.83 Perf Year116.45%
Cash/sh39.14 P/C16.57 EPS next 5Y8.86% ROE21.00% 52W Range271.37 - 664.64 Perf YTD72.69%
Dividend- P/FCF38.89 EPS past 5Y44.00% ROI16.10% 52W High-4.08% Beta0.56
Dividend %- Quick Ratio3.70 Sales past 5Y22.80% Gross Margin89.70% 52W Low134.92% ATR18.52
Employees8100 Current Ratio4.20 Sales Q/Q33.20% Oper. Margin30.50% RSI (14)52.80 Volatility2.33% 3.01%
OptionableYes Debt/Eq0.06 EPS Q/Q35.90% Profit Margin28.60% Rel Volume0.87 Prev Close648.43
ShortableYes LT Debt/Eq0.06 EarningsAug 05 BMO Payout0.00% Avg Volume1.27M Price637.50
Recom2.10 SMA200.40% SMA503.30% SMA20035.23% Volume414,882 Change-1.69%
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
Aug-05-20 11:00AM  
10:46AM  
10:29AM  
09:02AM  
08:36AM  
08:32AM  
08:15AM  
07:24AM  
06:59AM  
06:53AM  
06:47AM  
06:30AM  
Aug-04-20 06:27PM  
05:33PM  
12:16PM  
11:24AM  
07:38AM  
06:30AM  
01:32AM  
12:32AM  
Aug-03-20 07:02PM  
08:30AM  
07:03AM  
07:00AM  
06:45AM  
05:45AM  
01:49AM  
Jul-31-20 06:27PM  
Jul-30-20 07:32PM  
06:43PM  
03:01PM  
02:13PM  
10:56AM  
Jul-29-20 10:25PM  
09:00PM  
05:50PM  
12:33PM  
07:24AM  
02:28AM  
01:53AM  
Jul-28-20 03:18PM  
07:12AM  
Jul-24-20 11:38AM  
Jul-23-20 05:50PM  
05:05PM  
11:54AM  
Jul-22-20 08:20PM  
Jul-20-20 11:38AM  
10:00AM  
Jul-19-20 08:33AM  
Jul-17-20 07:47AM  
07:02AM  
07:00AM  
Jul-13-20 05:50PM  
Jul-12-20 10:58AM  
Jul-11-20 05:47PM  
06:26AM  
Jul-10-20 01:15PM  
10:43AM  
08:23AM  
Jul-09-20 04:09PM  
02:55PM  
11:53AM  
10:12AM  
09:41AM  
Jul-08-20 04:30PM  
12:27PM  
10:22AM  
09:34AM  
08:17AM  
Jul-07-20 07:09PM  
06:48PM  
05:58PM  
04:21PM  
02:56PM  
02:18PM  
01:15PM  
12:51PM  
12:11PM  
11:58AM  
10:49AM  
10:45AM  
10:10AM  
09:53AM  
09:39AM  
09:32AM  
07:22AM  
07:17AM  
07:14AM  
07:03AM  
07:00AM  
Jul-06-20 03:39PM  
02:02PM  
01:20PM  
10:47AM  
10:43AM  
08:48AM  
08:35AM  
08:30AM  
08:24AM  
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It also has a collaboration with Zai Lab Limited and Intellia Therapeutics, Inc. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Landry Robert EEVP Finance CFOJul 21Sale647.58391253,20424,669Jul 22 04:30 PM
Fenimore Christopher R.VP ControllerJul 21Sale642.043,7092,381,31717,501Jul 22 04:31 PM
Fenimore Christopher R.VP ControllerJul 20Option Exercise156.0112,2241,907,01525,277Jul 22 04:31 PM
Landry Robert EEVP Finance CFOJul 20Option Exercise491.438,5004,177,16029,671Jul 22 04:30 PM
Landry Robert EEVP Finance CFOJul 14Sale640.50579370,85023,973Jul 14 04:17 PM
MURPHY ANDREW JEVP ResearchJul 14Sale633.482,3801,507,67741,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 14Sale623.893,9292,451,27744,331Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Option Exercise30.6313,000398,19054,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Sale628.508,0005,028,02241,951Jul 15 04:51 PM
Landry Robert EEVP Finance CFOJul 09Option Exercise399.663,0001,198,98026,973Jul 13 04:28 PM
Landry Robert EEVP Finance CFOJul 08Sale639.661,160742,01123,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Option Exercise33.427,500250,650122,915Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Option Exercise391.921,706668,6162,349Jul 08 04:14 PM
Landry Robert EEVP Finance CFOJul 07Option Exercise524.4712,5006,555,85033,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Sale650.163,0001,950,474400Jul 08 04:16 PM
SING GEORGE LDirectorJul 07Sale650.007,5004,875,000115,415Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Sale650.001,7061,108,900643Jul 08 04:14 PM
BROWN MICHAEL SDirectorJul 01Option Exercise413.333,6131,493,3614,256Jul 02 04:02 PM
BROWN MICHAEL SDirectorJul 01Sale607.623,6132,195,342643Jul 02 04:02 PM
RYAN ARTHUR FDirectorJul 01Sale609.7010060,97028,643Jul 02 04:01 PM
SING GEORGE LDirectorJun 29Sale608.913,0001,826,7211,400Jun 29 04:08 PM
Landry Robert EEVP Finance CFOJun 29Sale612.57400245,02923,973Jun 30 04:02 PM
Landry Robert EEVP Finance CFOJun 23Sale631.27512323,21224,373Jun 24 04:03 PM
Landry Robert EEVP Finance CFOJun 22Option Exercise555.678,9004,945,46333,273Jun 24 04:03 PM
Bassler Bonnie LDirectorJun 19Option Exercise391.922,5591,002,9233,202Jun 22 04:18 PM
Bassler Bonnie LDirectorJun 19Sale630.022,5591,612,211643Jun 22 04:18 PM
Fenimore Christopher R.VP ControllerJun 16Sale590.893,5562,101,21515,277Jun 17 04:02 PM
Fenimore Christopher R.VP ControllerJun 15Option Exercise47.079,406442,74220,323Jun 17 04:02 PM
Zoghbi Huda YDirectorJun 11Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 11Sale625.001,7061,066,250643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 11Sale612.08988604,73124,373Jun 12 04:01 PM
Landry Robert EEVP Finance CFOJun 10Option Exercise272.703,500954,45027,873Jun 12 04:01 PM
Zoghbi Huda YDirectorJun 10Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 10Sale610.241,7061,041,068643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 09Sale608.014,2712,596,79224,373Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Option Exercise413.3310,8384,479,67117,481Jun 09 04:05 PM
Landry Robert EEVP Finance CFOJun 08Option Exercise272.7015,5004,226,85029,860Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Sale592.9510,8386,426,3626,643Jun 09 04:05 PM
Bassler Bonnie LDirectorJun 05Option Exercise391.922,5591,002,9233,202Jun 05 04:15 PM
Bassler Bonnie LDirectorJun 05Sale600.002,5591,535,400643Jun 05 04:15 PM
RYAN ARTHUR FDirectorJun 01Sale603.2310060,32328,743Jun 02 04:04 PM
SING GEORGE LDirectorMay 29Sale596.511,000596,5102,400Jun 01 04:08 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale578.941,000578,9406,643Jun 01 04:02 PM
SING GEORGE LDirectorMay 28Sale579.001,000579,0002,900Jun 01 04:08 PM
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM
STAHL NEILEVP Research and DevelopmentMay 11Sale569.525,3053,021,28911,380May 11 04:39 PM
STAHL NEILEVP Research and DevelopmentMay 08Option Exercise52.0312,500650,37523,880May 11 04:39 PM
Zoghbi Huda YDirectorMay 07Option Exercise391.925,1182,005,8475,761May 08 04:03 PM
Zoghbi Huda YDirectorMay 07Sale566.525,1182,899,461643May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 07Sale564.3239,58322,337,30628,251May 08 04:04 PM
BROWN MICHAEL SDirectorMay 07Sale562.001,8091,016,658643May 07 04:14 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise177.8215,0002,667,30016,830May 08 04:03 PM
BROWN MICHAEL SDirectorMay 06Option Exercise371.985,4702,034,7395,863May 07 04:14 PM
RYAN ARTHUR FDirectorMay 06Option Exercise373.6750,12418,729,67078,967May 07 06:22 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 06Option Exercise52.0385,5794,452,67596,051May 08 04:04 PM
RYAN ARTHUR FDirectorMay 06Sale550.8850,12427,612,50928,843May 07 06:22 PM
GOLDSTEIN JOSEPH LDirectorMay 06Sale560.002,0001,120,0007,643May 06 04:19 PM
Tessier-Lavigne MarcDirectorMay 06Sale563.9715,0008,459,4961,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 01Sale520.3710052,03728,843May 04 04:02 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale565.483,5221,991,61116,216Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale570.301,7781,013,98514,438Apr 20 07:27 PM
Landry Robert EEVP Finance CFOApr 20Sale566.943,2501,842,53924,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Option Exercise59.2011,622688,02222,458Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Option Exercise272.7012,5003,408,75036,873Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Sale557.382,2671,263,58614,438Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Sale557.68991552,66124,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 16Option Exercise59.205,000296,00019,438Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 16Option Exercise272.704,0001,090,80028,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 15Sale518.212,2621,172,18714,438Apr 16 04:04 PM
Landry Robert EEVP Finance CFOApr 15Sale518.49853442,27624,373Apr 16 04:03 PM
Landry Robert EEVP Finance CFOApr 14Option Exercise272.703,500954,45027,873Apr 16 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 14Option Exercise59.205,000296,00019,438Apr 16 04:04 PM
STAHL NEILEVP Research and DevelopmentApr 14Sale521.075,4972,864,30711,380Apr 15 04:17 PM
STAHL NEILEVP Research and DevelopmentApr 13Option Exercise52.0313,079680,50024,459Apr 15 04:17 PM
Landry Robert EEVP Finance CFOApr 13Sale509.79828422,10824,373Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 09Option Exercise272.703,500954,45027,873Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 07Sale497.52696346,27124,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 06Option Exercise272.703,000818,10027,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 03Sale494.28683337,59224,373Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Option Exercise272.703,000818,10028,726Apr 03 04:49 PM
Landry Robert EEVP Finance CFOApr 02Sale495.8810552,06825,056Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Sale489.321,248610,67225,161Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 02Sale489.986,7973,330,40614,438Apr 03 04:08 PM
Landry Robert EEVP Finance CFOApr 01Option Exercise272.706,0001,636,20026,937Apr 03 04:49 PM
Fenimore Christopher R.VP ControllerApr 01Option Exercise30.631,20036,75614,297Apr 03 04:05 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 01Option Exercise59.2015,000888,00023,924Apr 03 04:08 PM
Landry Robert EEVP Finance CFOApr 01Sale488.02600292,81124,373Apr 03 04:49 PM
Fenimore Christopher R.VP ControllerApr 01Sale488.411,200586,09613,097Apr 03 04:05 PM
RYAN ARTHUR FDirectorApr 01Sale483.8510048,38528,943Apr 01 06:49 PM
RYAN ARTHUR FDirectorMar 30Sale466.6910046,66929,043Apr 01 06:49 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 10Sale470.47117,81555,428,041517,799Mar 11 04:05 PM